Llwytho...
Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S
Precision medicine has revolutionized the treatment of patients in EGFR driven non-small cell lung cancer (NSCLC). Targeted drugs show high response rates in genetically defined subsets of cancer patients and markedly increase their progression-free survival as compared to conventional chemotherapy....
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Chem Sci |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Royal Society of Chemistry
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6886544/ https://ncbi.nlm.nih.gov/pubmed/31857889 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1039/c9sc03445e |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|